| NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal Cancers (NCT07775859) | Peking University Cancer Hospital & Institute | 2026-09-01 |
| SHR-A1904 in Advanced Colorectal Cancer: an Exploratory Study (NCT07700719) | Peking University Cancer Hospital & Institute | 2026-07-28 |
| Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and Vomiting (NCT07692451) | Peking University Cancer Hospital & Institute | 2026-07-15 |
| Safety and Efficacy of NOM and OPFS Versus RO for dMMR/MSI-H or POLE-Mutated Gastrointestinal Cancers (NCT07642323) | Peking University Cancer Hospital & Institute | 2026-07-15 |
| Development and Validation of a Colorectal Cancer Diagnostic Model (NCT07692555) | Peking University Cancer Hospital & Institute | 2026-07-15 |
| Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC (NCT07567326) | Peking University Cancer Hospital & Institute | 2026-07-01 |
| Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer (NCT07653451) | Peking University Cancer Hospital & Institute | 2026-07-01 |
| 18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy (NCT07724535) | Peking University Cancer Hospital & Institute | 2026-06-24 |
| Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers (NCT07656740) | Peking University Cancer Hospital & Institute | 2026-06-15 |
| 68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors (NCT07639801) | Peking University Cancer Hospital & Institute | 2026-06-01 |
| 5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors (NCT07589101) | Peking University Cancer Hospital & Institute | 2026-06-01 |
| Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair Deficiency (NCT07595523) | Peking University Cancer Hospital & Institute | 2026-06-01 |
| Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma (NCT05321316) | Peking University Cancer Hospital & Institute | 2026-05-31 |
| Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma (NCT07622706) | Peking University Cancer Hospital & Institute | 2026-05-30 |
| Abemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant Therapy (NCT07599137) | Peking University Cancer Hospital & Institute | 2026-05-30 |
| Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer (NCT07745322) | Peking University Cancer Hospital & Institute | 2026-05-20 |
| Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging (NCT07527806) | Peking University Cancer Hospital & Institute | 2026-05-01 |
| Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors (NCT07529002) | Peking University Cancer Hospital & Institute | 2026-04-14 |
| Comparison of [68Ga]Ga-CTR-FAPI and 18F-FDG PET/MRI for Lymph Node Staging in Rectal Cancer (NCT07552207) | Peking University Cancer Hospital & Institute | 2026-04-01 |
| SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study (NCT07417241) | Peking University Cancer Hospital & Institute | 2026-03-31 |
| Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer (NCT07470203) | Peking University Cancer Hospital & Institute | 2026-03-31 |
| Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone (NCT07381543) | Peking University Cancer Hospital & Institute | 2026-03-01 |
| Hand and Foot Bath for Taxane-Induced Peripheral Neurotoxicity (NCT07344974) | Peking University Cancer Hospital & Institute | 2026-02-01 |
| Standardized Management of Esophageal Fistula in Esophageal Squamous Cell Carcinoma (NCT07353541) | Peking University Cancer Hospital & Institute | 2026-02-01 |
| PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor (NCT07442292) | Peking University Cancer Hospital & Institute | 2026-02-01 |
| CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer (NCT07383285) | Peking University Cancer Hospital & Institute | 2026-02-01 |
| Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal Cancer (NCT07394192) | Peking University Cancer Hospital & Institute | 2026-02-01 |
| Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD (NCT07357532) | Peking University Cancer Hospital & Institute | 2026-01-31 |
| A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment (NCT07413042) | Peking University Cancer Hospital & Institute | 2026-01-20 |
| Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg (NCT07298148) | Peking University Cancer Hospital & Institute | 2026-01-01 |
| Autologous Probiotics in Patients With Defunctioning Ileostomy Following LAR for Rectal Cancer (NCT07366047) | Peking University Cancer Hospital & Institute | 2025-12-31 |
| Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer (NCT07241819) | Peking University Cancer Hospital & Institute | 2025-11-30 |
| Monarch Robotic Bronchoscopy for Lung Nodule ICG Dye Marking Before VATS (NCT07177924) | Peking University Cancer Hospital & Institute | 2025-10-10 |
| High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC (NCT07182708) | Peking University Cancer Hospital & Institute | 2025-10-01 |
| A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases (NCT07177950) | Peking University Cancer Hospital & Institute | 2025-09-30 |
| Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC (NCT07200154) | Peking University Cancer Hospital & Institute | 2025-09-30 |
| A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI (NCT07165418) | Peking University Cancer Hospital & Institute | 2025-09-25 |
| Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach (NCT07178340) | Peking University Cancer Hospital & Institute | 2025-09-18 |
| Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor (NCT07152535) | Peking University Cancer Hospital & Institute | 2025-09-01 |
| Chinese Ostomy Collaboration Group (COCG) Clinical Study -SITI Classification (NCT07111429) | Peking University Cancer Hospital & Institute | 2025-08-15 |
| QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma (NCT07049185) | Peking University Cancer Hospital & Institute | 2025-07-15 |
| Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM (NCT07031570) | Peking University Cancer Hospital & Institute | 2025-07-01 |
| JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma (NCT07024147) | Peking University Cancer Hospital & Institute | 2025-07-01 |
| Comparative Research on the Accuracy of Margin Interpretation in Breast-Conserving Surgery for Breast Cancer: Cell Microscopic Imaging and Standard Frozen Pathology (NCT07029646) | Peking University Cancer Hospital & Institute | 2025-07-01 |
| Evaluating AI and Human Expert Decisions in Colorectal Cancer (NCT07045207) | Peking University Cancer Hospital & Institute | 2025-07-01 |
| A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery (NCT06674252) | Peking University Cancer Hospital & Institute | 2025-06-13 |
| Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer (NCT07004712) | Peking University Cancer Hospital & Institute | 2025-06-01 |
| Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis (NCT07007728) | Peking University Cancer Hospital & Institute | 2025-06-01 |
| Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach (NCT06992362) | Peking University Cancer Hospital & Institute | 2025-05-20 |
| A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC (NCT06969612) | Peking University Cancer Hospital & Institute | 2025-05-15 |
| Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration (NCT06991790) | Peking University Cancer Hospital & Institute | 2025-05-01 |
| 68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy (NCT06716788) | Peking University Cancer Hospital & Institute | 2025-05-01 |
| A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer (NCT06869226) | Peking University Cancer Hospital & Institute | 2025-04-30 |
| Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure (NCT07087223) | Peking University Cancer Hospital & Institute | 2025-04-08 |
| Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD (NCT06924710) | Peking University Cancer Hospital & Institute | 2025-04-06 |
| Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer. (NCT06894797) | Peking University Cancer Hospital & Institute | 2025-04-01 |
| A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma (NCT06869213) | Peking University Cancer Hospital & Institute | 2025-03-31 |
| A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma (NCT07000617) | Peking University Cancer Hospital & Institute | 2025-03-21 |
| Trop-2 Targeted PET Probes in Advanced TNBC (NCT07046455) | Peking University Cancer Hospital & Institute | 2025-03-01 |
| Clinical Application of CAIX-Targeted PET Imaging in Tumors (NCT07590310) | Peking University Cancer Hospital & Institute | 2025-03-01 |
| Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC (NCT06849167) | Peking University Cancer Hospital & Institute | 2025-03-01 |
| Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy (NCT06869239) | Peking University Cancer Hospital & Institute | 2025-02-25 |
| Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer (NCT06784206) | Peking University Cancer Hospital & Institute | 2025-02-01 |
| Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD (NCT06780839) | Peking University Cancer Hospital & Institute | 2025-01-15 |
| Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (NCT06768307) | Peking University Cancer Hospital & Institute | 2025-01-07 |
| TF-antigen Targeting Molecular Probe for PET Imaging in Solid Tumors (NCT06755086) | Peking University Cancer Hospital & Institute | 2025-01-06 |
| First Human Trial of Targeting MDM2/MDMX PET Imaging (NCT06443762) | Peking University Cancer Hospital & Institute | 2025-01-03 |
| Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy (NCT06909604) | Peking University Cancer Hospital & Institute | 2025-01-01 |
| CD147 Targeting Peptide Probe for PET Imaging in Solid Tumors (NCT06720298) | Peking University Cancer Hospital & Institute | 2025-01-01 |
| Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer (NCT06745219) | Peking University Cancer Hospital & Institute | 2025-01-01 |
| MMP14(MT1-MMP) Targeting Bicyclic Peptide Probe for PET Imaging in Solid Tumors (NCT06719856) | Peking University Cancer Hospital & Institute | 2025-01-01 |
| Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma (NCT06757387) | Peking University Cancer Hospital & Institute | 2024-12-30 |
| Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging (NCT06715020) | Peking University Cancer Hospital & Institute | 2024-12-10 |
| Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer (NCT06926179) | Peking University Cancer Hospital & Institute | 2024-12-01 |
| Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions (NCT06648317) | Peking University Cancer Hospital & Institute | 2024-11-21 |
| EGFR Mutation Targeting Molecular Probe for PET Imaging (NCT06641674) | Peking University Cancer Hospital & Institute | 2024-11-15 |
| A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors (NCT06728189) | Peking University Cancer Hospital & Institute | 2024-11-14 |
| Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC (NCT06690541) | Peking University Cancer Hospital & Institute | 2024-11-10 |
| The Role and Safety of Radiofrequency Ablation in Recurrent Liver Metastasis of Colorectal Cancer (NCT06609434) | Peking University Cancer Hospital & Institute | 2024-10-01 |
| A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens (NCT06732505) | Peking University Cancer Hospital & Institute | 2024-09-29 |
| 68Ga-ICAM-1pep PET/CT in Cancer Patients (NCT04596670) | Peking University Cancer Hospital & Institute | 2024-09-20 |
| Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study (NCT07251868) | Peking University Cancer Hospital & Institute | 2024-08-01 |
| A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma (NCT06472895) | Peking University Cancer Hospital & Institute | 2024-07-20 |
| Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer (NCT06306755) | Peking University Cancer Hospital & Institute | 2024-06-25 |
| Molecular Imaging of Gastric Cancer Metastatic Lymph Nodes with 99mTc-3PRGD2 Probe. (NCT06435741) | Peking University Cancer Hospital & Institute | 2024-06-06 |
| HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC (NCT06548529) | Peking University Cancer Hospital & Institute | 2024-06-01 |
| Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer (NCT06443671) | Peking University Cancer Hospital & Institute | 2024-06-01 |
| A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma (NCT06424626) | Peking University Cancer Hospital & Institute | 2024-05-28 |
| RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression (NCT06420973) | Peking University Cancer Hospital & Institute | 2024-05-16 |
| Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors (NCT05322512) | Peking University Cancer Hospital & Institute | 2024-05-01 |
| The Efficacy and Safety of Liangxue Ointment in the Treatment of Hand-foot Syndrome Caused by VEGFR-TKI Drugs (NCT06583369) | Peking University Cancer Hospital & Institute | 2024-03-25 |
| A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (NCT06313957) | Peking University Cancer Hospital & Institute | 2024-03-14 |
| Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe (NCT06203119) | Peking University Cancer Hospital & Institute | 2024-03-06 |
| Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma (NCT06211114) | Peking University Cancer Hospital & Institute | 2024-02-09 |
| Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer (NCT06209099) | Peking University Cancer Hospital & Institute | 2024-01-17 |
| A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy (NCT06549907) | Peking University Cancer Hospital & Institute | 2024-01-10 |
| Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC (NCT06360042) | Peking University Cancer Hospital & Institute | 2024-01-01 |
| Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors (NCT06454955) | Peking University Cancer Hospital & Institute | 2024-01-01 |
| Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab (NCT06141265) | Peking University Cancer Hospital & Institute | 2023-11-01 |
| the Beijing Randomized Study Of Prostate Cancer Screening (NCT05961514) | Peking University Cancer Hospital & Institute | 2023-10-31 |